BOTULINUM TOXIN: CURRENT USE IN UROLOGY

Czech version

Authors: Vladimír Šámal
Authors‘ workplace: Urologické oddělení ; Krajská nemocnice Liberec, a. s.
Published in: Ces Urol 2009; 13(3): 199-206
Category: Review article

Overview

Botulinum toxin is a presynaptic neuromuscular blocking agent, which induce reversible muscle weakness. From feared poison he changed to intensive researched drug. Many medical disciplines have discovered the indication for treatment. In urology the first experiences is from 1988, when botulinum toxin was used to treat detrusor-sphincter dyssynergia. Nowadays is mostly used to treat neurogenic detrusor overactivity. Effect of treatment can last 6–9 month and continence is restored in about 80% of the patients. Based on actual knowledges is possible to repeat treatment. Influece on decrease of prostatae volume and painful bladder syndrom is still in phase of clinical trials.

Key words:
botulinum toxin, detrusor overactivity, detrusor sphincter dyssynergia, urinary retention, benign prostatic enlargement.

Sources

1. Krhut J. Neurourologie. Praha: Galén 2005; 44–46.

2. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Uro 2003; 44: 165–174.

3. Reitz J, Schurch B. Botulinum toxin type BoNT/BoNT/A injection for management of type A resistant neuorogenic detrusor overactivity. J Urol 2004; 171: 804–805.

4. Beafour Ipsen Int. Dysport: Scinetific brochure, Feb, 2001.

5. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 692–596.

6. Haferkapm A, Schurch BoNT/A, Reitz A, Krengel U, Grosse J, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neuorogenic bladder. Eur Urol 2004; 46: 784–791.

7. Truzzi JC, Bruschini H, Simoneti R, Miguel S. What is the best dose for intravesical botulinum A toxin injection in overactive bladder treatment? A prospective randomized preliminary study. Join meeting of the International Continence Society (ICS) ant the International Uro-Gynecological association (IUGA), Paris, France, Aug 25–27, 2004.

8. Gausse A, Tunuguntla HS, Rodroiguez G, Velzazquez D. Dose finding prospective randomized study to evaluate the efficacy and safety of botulinum A toxin for refractory idiopathic overactive bladder Interanational Continence Society Annual Meeting, Montreal, Canada, Aug 2005: Abstract 254.

9. Schurch B, Stohrer M, Kramer G et al. Botulinum toxin A to treat detrusor hyperreflexia in spinal cord injured patient. Neurourol Urodyn 2001; 20: 521–522.

10. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers´ product summaries. J Clin Pharm Ther 2007; 32: 387–402.

11. Patel A, Patterson J, Chapple C. Botulinum Toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol 2006; 50: 684–710.

12. Schurch B, de Seze M, Denys P, et al. Botulinumtoxin type A is safe and effective treatment for neurogenic urinary incontinence: results of single treatment, randomized, placebo controlled 6 month study. J Urol 2005; 174: 196–200.

13. Giannantoni A, Mearini E, Di Stasti et al. New therapeutic options for refractory neurogenic detruzor overactivity. Minerva Urol Nefrol 2004; 56: 79–87.

14. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox^®) intradetrusor injections in adults with neurogenic detruzor overactivity /neurogenic overactive bladder: a systematic literature review. Eur Urol 2008; 53: 275–287.

15. Krhut J, Kopecký J, Hradílek P, Zapletalová O, Tvrdík J. Využití léčby neurogenních dysfunkcí dolních cest močových aplikací botulinumtoxinu do detruzoru. Česká Urologie 2007; 11(3): 154–158.

16. Giannantoni A, Mearini E, Del Zengrano M, Perena M. Six year follow-up of botulinum toxin A intradetrusorial injection in patient with refractory neurogenic detrusor overactivity: clinical and urodynamic results: Eur Urol (in press); doi:10.1016/j.eururo.2008.08.048.

17. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler C, Daskygypta P. Quality of life changes in patient with neurogenic versus idopatic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006; 49: 528–535.

18. Novara G. Botulinum neurotoxin type A: the poison that can treat the sick. Eur Urol 2008; doi 10.1016/j.eururo.2008.09.003.

19. Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 1997; 63: 474–476.

20. Dykstra D, Sidi A, Scott A, et al. Effects of botulinum-A toxin on detrusor sphincter dyssynergia in spinal cord injury patiens. J Urol 1988; 139: 919–922.

21. Schurch B, Hauri D, Rodic BoNT/A, Curt A, Mayer M, Rosier AB. Botulinum-A toxin as a treatment of detrusor – sphincter dyssynergia in spinal cord disease. Spinal cord 1998; 36(2): 91–94.

22. de Séze M, Petit H, Gallien P, de Séze MP. et al. Botulinum A toxin and detrusor sphincter dyssynergie: A double-blind lidocain-controlled study in 13 patinent with spinal cord dinase. Eur Urol 2002; 42: 56–62.

23. Phelan MW, Franks K, Somogyi G, YokoyamaT, Fraser M, Lavelle JP. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001; 165: 1107–1110.

24. Kuo H. Effectiveness of periurethral botulinum toxin injection in the treatment of neurol voiding dysfunction due to detrusor underactivity an non-relaxing urethral Neuol Urodyn 2002; 21(4): 387–388.

25. Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG. Botulinum toxin in the treatment of chronic urinary retention in woman. Br J Urol 1992; 70(4): 387–390.

26. Dogweiller R, Zermann DH, Ishigooka M, Schmidt R. Botox-induced prostatic involution. Prostate 1998; 37: 44–50.

27. Silva J, Silva c, Saraiva L, Silva A, Pinto R, Dinis P, Cruz F. Intraprostatic botulinumtoxin A injection in patient unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resupmption. Eur Uro 2008; 53: 153–159.

28. Oecomonou A, Madersbacher H, Kiss G, Berger T, Melekos M, Rehder P. Is botulinum neurotoxin type A (BoNT/A) a novel therapy for Lowel urinary tract symptoms due to benign prostatic enlargement? A review of literature. Eur Urol 2008; 54: 765–777.

29. Giannantoni A,Constanti E, Di Stasi S, Tacini M. Botulinum A toxin intravesical injection in the treatment of painful bladder syndrome: A pilot study. Eur Urol 2006; 49: 704-7096.

30. Ghei M, Marai BH, Miller R, et al. Effects of botulinum toxin BoNT/A on refraktory detrusor overactivity: a randomised, double blind, placebo-controlled, crossover trial. J Urol 2005; 174: 1873–1878.

31. Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: Distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992; 52: 884–888.

Labels

Paediatric urologist Nephrology Urology

ABOUT ABSTRACTS

Excursion to medical research information – impact factor and H-index

Initial experience with intradetrusor application of botulinum A toxin in children with detrusor overactivity

Our first experiences with thermo-expandable shape-memory Memokath stents

Ruptured kidney as complication of extracorporeal shock wave lithotripsy

Pen in urinary bladder

30. Annual Meeting of the Czech Working Group for Pediatric Nephrology 20. Annual Meeting of the Czech Working Group for Pediatric Urology

Article was published in

Czech Urology

2009 Issue 3